Navigation Links
Medimetriks Pharmaceuticals Launches Company's First Prescription Brands
Date:1/12/2009

Medimetriks introduces 3 new therapies for the Dermatology and Podiatry Markets

FAIRFIELD, N.J., Jan. 12 /PRNewswire/ -- Medimetriks Pharmaceuticals, Inc. announced today that the Company launched its first prescription topical therapies into the Dermatology and Podiatry markets. The three new brands are Pacnex(TM) (7% Benzoyl Peroxide) Wash, a topical treatment for acne; Sumaxin(TM) (Sodium Sulfacetamide 10% & Sulfur 4%) Cleansing Pads, a topical treatment for acne, rosacea and seborrheic dermatitis; and Uramaxin(TM) (45% Urea) Nail Gel, a treatment for diseased and damaged nails.

A unique attribute of these therapies is the addition of natural ingredients. The vehicles for Pacnex(TM) Wash and Sumaxin(TM) Cleansing Pads both contain Green Tea and Aloe, natural ingredients gaining wide acceptance. Green Tea is known for its antioxidant properties and Aloe for its natural soothing benefits. Sumaxin(TM) Cleansing Pads also have the unique attribute of a reduced sulfur odor, addressing a common complaint with sulfur-based topical therapies. Uramaxin(TM) Nail Gel offers a vehicle containing Menthol, Camphor and Eucalyptus Oil, ingredients designed to naturally mask the odor often associated with diseased nails.

"Since the launch of our company eight months ago, Medimetriks' staff has leveraged its expertise to create and bring to market high quality topical therapies that offer elegant formulations, provide value to patients, and enhance patient care," stated Bradley Glassman, President and CEO of Medimetriks. "These brands were developed with the objective of meeting the therapeutic needs of both physicians and their patients, and we believe we have developed three brands that meet that objective."

Medimetriks' new field force is strategically located in the most significant markets in which the new brands compete. "Physicians are now seeing Medimetriks Sales Representatives in their offices," said Mr. Glassman. "These sales professionals are highly trained and charged with the mission of championing patient care through the ethical promotion of skincare therapy, delivering knowledge, service and value to our core physician audiences and their patients."

With the launch of these brands into the Dermatology and Podiatry markets, Medimetriks will begin to establish a leadership role in supporting the Dermatology and Podiatry communities. The Company will actively support the organizations critical to these specialties and provide education important to their patients.

Medimetriks is planning for the launch of additional topical prescription therapies in the first quarter of 2009.

Important Product Safety Information:

Pacnex(TM) Wash is for external use only. Avoid contact with eyes, lips or mucous membranes. If severe irritation develops, discontinue use of Pacnex(TM) Wash. While using Pacnex(TM) Wash, patients should be advised to avoid unnecessary sun exposure. Please see full Prescribing Information available at www.medimetriks.com.

Sumaxin(TM) Cleansing Pads are contraindicated in persons with known or suspected hypersensitivity to sulfonamides or sulfur. Sumaxin(TM) Cleansing Pads are not to be used by patients with kidney disease. Although rare, topical sodium sulfacetamide may cause local irritation. Please see full Prescribing Information available at www.medimetriks.com.

Uramaxin(TM) Nail Gel is for external use only. Avoid contact with eyes, lips or mucous membranes. Transient stinging, burning, itching or irritation may occur and normally disappear on discontinuing the medication. Use as directed. Please see full Prescribing Information available at www.medimetriks.com.

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals, Inc. develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at www.medimetriks.com, call (973) 882-7512 or fax (973) 882-7502.


'/>"/>
SOURCE Medimetriks Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
2. Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines
3. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
4. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
5. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
6. Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare
7. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
8. Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
9. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
10. MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009
11. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... "I had a terrible time trying to get my grandson ... if the nebulizer had a more child-friendly design, then children would be more likely ... patent-pending NEBY to avoid the need to deliver medication via a nebulizer mask. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
(Date:12/8/2016)... NY (PRWEB) , ... December 08, 2016 , ... ... is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods ... in JMIR Medical Informatics . , Results of the comparative usability study ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
(Date:12/8/2016)... Research and Markets has announced the addition of the "Global ... - Forecast to 2025" report to their offering. ... , , ... a CAGR of around 3.2% from 2015 to 2025. Some of ... extracellular microelectrode arrays and intracellular microelectrodes, research in left-to-right shunt detection ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
Breaking Medicine Technology: